RPL21 Antibody

What is RPL21 and what cellular functions has it been associated with?

RPL21 is a ribosomal protein with a calculated molecular weight of 19 kDa, though it typically appears at 20-25 kDa in western blot analyses . While traditionally considered a structural component of the 60S ribosomal subunit, recent research reveals RPL21 has significant extraribosomal functions, particularly in cancer biology. Studies demonstrate its involvement in cell proliferation regulation, DNA replication, cell cycle progression, and apoptosis pathways . RPL21 has been implicated in pancreatic cancer and colorectal cancer development through multiple molecular pathways, including regulation of E2F1 transcription factor and interaction with LAMP3 to promote invasion and metastasis .

To study RPL21 functions, researchers should consider dual approaches combining antibody-based detection with functional studies using knockdown/knockout techniques to distinguish canonical ribosomal functions from cancer-specific roles.

What are the recommended applications and dilutions for RPL21 antibodies?

RPL21 antibodies can be utilized across multiple experimental applications with the following recommended dilutions:

It's important to note that optimal dilutions are sample-dependent and should be determined experimentally for each new cell line or tissue type . For IHC applications, antigen retrieval with TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 may be used as an alternative .

How should sample preparation be optimized for RPL21 detection?

For optimal RPL21 detection, sample preparation protocols should be tailored to the specific cellular localization patterns of the protein. While primarily a ribosomal component, RPL21 has been observed in multiple cellular compartments depending on cell type and physiological conditions.

For western blotting:

• Use RIPA buffer supplemented with protease inhibitors for whole cell lysates

• Consider nuclear/cytoplasmic fractionation to distinguish compartment-specific functions

• Include phosphatase inhibitors if investigating potential post-translational modifications

For immunohistochemistry:

• Test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval to determine optimal protocol

• Consider tissue-specific fixation times, as overfixation can mask RPL21 epitopes

• Include appropriate positive controls (human liver tissue has been validated)

When troubleshooting detection issues, remember that observed molecular weight (20-25 kDa) may differ from calculated weight (19 kDa) due to post-translational modifications .

How can RPL21 antibodies be used to investigate its role in cancer cell proliferation?

RPL21 has been identified as a critical regulator of cancer cell proliferation, particularly in pancreatic cancer cells. When designing experiments to study this relationship, researchers should consider:

• Combining antibody-based detection with functional studies:

  • Western blot with RPL21 antibodies to confirm expression levels before and after manipulation

  • Parallel tracking of proliferation markers (PCNA, Ki-67) alongside RPL21

• Downstream pathway analysis:

  • Following RPL21 knockdown, significant downregulation of mini-chromosome maintenance (MCM) protein family (MCM2-7), CCND1, and CCNE1 occurs in pancreatic cancer cell lines

  • These changes correlate with suppressed DNA replication and G1 cell cycle arrest

• Cell cycle analysis protocol:

  • After confirming RPL21 levels by western blot, perform flow cytometry analysis to determine distribution across cell cycle phases

  • Compare control versus RPL21-depleted cells to quantify G1 arrest

  • Complement with EdU incorporation assays to measure DNA synthesis rates

Research has demonstrated that RPL21 controls DNA replication and G1-S phase progression potentially through regulation of E2F1 transcription factor in pancreatic cancer cells , providing a mechanistic framework for investigation in other cancer types.

What methodologies are recommended for studying RPL21's interaction with other proteins?

To investigate RPL21's protein interactions, particularly with proteins like LAMP3 in colorectal cancer, several complementary approaches are recommended:

• Co-immunoprecipitation (Co-IP):

  • Use RPL21 antibody for pulldown followed by western blotting to detect interacting partners

  • Alternatively, use antibodies against suspected binding partners to co-precipitate RPL21

  • Include appropriate controls to confirm specificity of interactions

• GST/His pull-down assays:

  • These have successfully identified specific binding domains between RPL21 and LAMP3

  • Research has shown RPL21 directly binds to the aa 341–416 domain of LAMP3 via its aa 1–40 and aa 111–160 segments

  • This approach can delineate precise interaction domains for other binding partners

• Proximity ligation assay (PLA):

  • Provides spatial resolution of protein interactions in situ

  • Useful for confirming interactions observed in biochemical assays within their cellular context

• Functional validation:

  • After identifying interactions, employ dual knockdown/overexpression strategies to determine functional significance

  • In colorectal cancer models, the RPL21-LAMP3 interaction enhances RPL21 protein stability by suppressing ubiquitin-proteasome degradation

When interpreting results, consider that RPL21 may have different interactomes in different cellular compartments or under various physiological conditions.

How do I design control experiments for RPL21 antibody specificity validation?

Rigorous validation of RPL21 antibody specificity is critical for reliable research outcomes. A comprehensive validation approach should include:

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide before application

  • Disappearance of signal confirms epitope-specific binding

• Genetic controls:

  • siRNA knockdown should reduce signal intensity proportionally to knockdown efficiency

  • CRISPR/Cas9 knockout provides the gold standard negative control

  • Observe band at 20-25 kDa (observed molecular weight) that disappears after knockdown

• Multiple antibody validation:

  • Test antibodies from different sources or raised against different epitopes

  • Concordant results increase confidence in specificity

• Isotype controls:

  • Include matched isotype controls at equivalent concentrations

  • Helps identify non-specific binding, especially in immunohistochemistry

• Cross-reactivity testing:

  • If working with animal models, verify species reactivity

  • RPL21 antibody (15226-1-AP) has demonstrated reactivity with human, mouse, and rat samples

Documentation of these validation steps should be included in any publication to ensure reproducibility.

What is known about RPL21's role in cancer metastasis and how can it be studied?

Recent research has revealed RPL21's unexpected role in promoting colorectal cancer invasion and metastasis through interaction with LAMP3 . To investigate this function:

• In vitro metastasis assays:

  • Use wound healing, transwell migration, and invasion assays to assess the effect of RPL21 modulation

  • These assays have successfully demonstrated RPL21's promotion of CRC cell migration and invasion

• Focal adhesion (FA) analysis:

  • Immunofluorescence staining to observe focal adhesions

  • Research indicates RPL21 and LAMP3 promote formation of immature FAs through activation of the FAK/paxillin/ERK signaling pathway

  • Double staining with paxillin and phospho-FAK can reveal FA dynamics

• Cell adhesion assays:

  • Quantify adhesion to various extracellular matrix components

  • Compare control vs. RPL21-depleted cells to assess functional impact

• In vivo metastasis models:

  • Orthotopic colorectal cancer mouse models have been effective in investigating RPL21's impact on metastatic ability

  • Consider both experimental and spontaneous metastasis models

  • Confirm RPL21 expression in primary tumors and metastases by IHC

• Mechanistic investigations:

  • Examine TFEB transcriptional activity using dual-luciferase reporter assays

  • Research shows RPL21 activates TFEB transcriptional function to upregulate LAMP3 expression

When designing these experiments, include both gain- and loss-of-function approaches to establish causality rather than correlation.

How can transcriptomic approaches complement antibody-based RPL21 research?

Integrating transcriptomic analyses with antibody-based detection provides a more comprehensive understanding of RPL21 function:

• Transcriptome sequencing after RPL21 modulation:

  • This approach has successfully identified genes differentially regulated after RPL21 knockdown

  • In pancreatic cancer cells, genes involved in DNA replication and cell cycle were significantly downregulated

• Validation of transcriptomic findings:

  • qPCR confirmation of differentially expressed genes

  • Previous studies validated expression changes in AHR, THBS1, DDIT3, MKNK2 (upregulated) and E2F1, PCNA, CCND1, CCNE1, MCM2, MCM4, MCM5, MCM7, KIAA0101 (downregulated) after RPL21 knockdown

• Functional pathway analysis:

  • Bioinformatic analyses to identify enriched pathways

  • Western blot validation of key pathway components using specific antibodies

  • In pancreatic cancer, E2F1 transcription factor pathway was identified as a key mechanism

• Integration with clinical data:

  • Correlate RPL21 expression levels with patient outcomes

  • RPL21 has been associated with poor prognosis in colorectal cancer patients

This multi-omics approach allows researchers to move beyond correlation to establish mechanistic understanding of RPL21's diverse cellular functions.

How should discrepancies between different detection methods for RPL21 be resolved?

Researchers occasionally encounter conflicting results when detecting RPL21 using different methods. To systematically resolve these discrepancies:

• Consider epitope accessibility:

  • Different antibodies recognize different epitopes that may be differentially accessible depending on cellular context

  • For IHC applications, compare both TE buffer pH 9.0 and citrate buffer pH 6.0 antigen retrieval methods

• Account for protein modifications:

  • The discrepancy between calculated (19 kDa) and observed (20-25 kDa) molecular weight suggests post-translational modifications

  • These modifications might affect epitope recognition

  • Use phosphatase treatment before western blotting to eliminate phosphorylation-dependent differences

• Evaluate cellular compartmentalization:

  • RPL21 may have different localizations with distinct functions

  • Compare results from whole cell lysates versus subcellular fractions

  • Use nuclear/cytoplasmic fractionation to resolve compartment-specific expression patterns

• Consider detection sensitivity thresholds:

  • Western blot may detect low abundance forms not visible by IHC

  • Increase antibody concentration or use signal amplification systems for low-expressing samples

• Cross-validate with non-antibody methods:

  • Use RNA-seq or qPCR to confirm expression at mRNA level

  • Compare with mass spectrometry data when available

When publishing, transparently report these comparative analyses to advance methodological understanding in the field.

What methodological approaches can distinguish RPL21's ribosomal versus extraribosomal functions?

Differentiating between RPL21's canonical ribosomal role and its emerging extraribosomal functions requires specialized experimental design:

• Polysome profiling:

  • Separate free RPL21 from ribosome-associated protein

  • Western blot analysis of different fractions can identify non-ribosomal pools

  • Compare distribution in normal versus cancer cells

• Structure-function analysis:

  • Research has identified specific domains of RPL21 (aa 1–40 and aa 111–160) that interact with LAMP3

  • Create domain-specific mutations that selectively disrupt extraribosomal interactions while preserving ribosomal function

• Complementation studies:

  • Express mutant forms of RPL21 in knockdown backgrounds

  • Assess which functions can be rescued by specific mutants

  • This approach can separate ribosomal functions from cancer-specific roles

• Temporal analysis after acute depletion:

  • Use inducible knockdown systems

  • Monitor immediate versus delayed effects (immediate effects more likely represent direct extraribosomal functions)

• Subcellular localization:

  • Immunofluorescence with RPL21 antibodies at 1:200-1:800 dilution

  • Co-staining with ribosomal markers versus extraribosomal partners

  • Examine localization changes during cell cycle or stress conditions

These approaches collectively provide stronger evidence for distinguishing RPL21's diverse cellular roles beyond protein synthesis.

How might RPL21 antibodies be employed in developing targeted cancer therapies?

Given RPL21's emerging role in cancer progression, antibody-based research approaches can contribute to therapeutic development:

• Target validation strategies:

  • Use RPL21 antibodies to confirm expression in patient-derived xenografts

  • Correlate expression levels with response to conventional therapies

  • IHC with RPL21 antibodies at 1:20-1:200 dilution can effectively detect expression in tissue samples

• Mechanisms for therapeutic intervention:

  • Studies show RPL21 knockdown suppresses cancer cell proliferation and induces apoptosis specifically in cancer cells but not normal cells

  • This differential response provides a potential therapeutic window

  • The apoptosis-inducing effect observed in BxPC-3 and PANC-1 cells but not in normal HPDE6-C7 cells suggests cancer-specific vulnerability

• Combination therapy approaches:

  • Investigate synergy between RPL21 targeting and conventional therapies

  • Use RPL21 antibodies to monitor expression changes after treatment

  • Western blot analysis at 1:500-1:1000 dilution can track therapy-induced changes

• Biomarker development:

  • Assess RPL21 as a prognostic/predictive biomarker

  • Develop standardized IHC protocols with established scoring systems

  • Colorectal cancer research suggests RPL21 expression correlates with tumor invasiveness and poor prognosis

These research directions highlight the potential translational applications of fundamental RPL21 antibody-based research in the oncology field.